Pfizer Wins RAPAMUNE Patent Case in Delaware District Court

Thu Jan 31, 2013 8:00am EST

* Reuters is not responsible for the content in this press release.

NEW YORK--(Business Wire)--
Pfizer Inc. said today that the United States District Court for the District of
Delaware ruled that Pfizer`s patent covering a method for using sirolimus, the
active ingredient in RAPAMUNE, for the inhibition of organ transplant rejection
is valid and infringed. The company brought a patent infringement action in
April 2010 against the generic company Watson Laboratories, Inc-Florida (now
known as Actavis) and three other Watson entities after Watson applied to the
FDA to market a generic version of RAPAMUNE. The Court`s decision prevents
Watson from marketing its generic version of RAPAMUNE in the U.S. before
Pfizer`s patent expires, pending a possible appeal by Watson. 

The patent at issue in the lawsuit is U.S. Patent No. 5,100,899, which including
pediatric exclusivity, expires January 7, 2014. In response to the decision, Amy
Schulman, Executive Vice President and General Counsel for Pfizer, said, "We are
pleased with the Court`s decision, recognizing the validity of our patent." 

In the United States, RAPAMUNE is indicated for the prevention of organ
transplant rejection in kidney transplant patients aged 13 years and older. 

Important Safety Information

* There is an increased risk of developing infections or certain cancers,
especially lymphoma and skin cancers.Rapamune has not been shown to be safe and
effective in people who have had liver or lung transplants. Serious
complications and death may happen in people who take Rapamune after a liver or
lung transplant.You should not take Rapamune if you have had a liver or lung
transplant without talking with your doctor.
* Do not take Rapamune if you know you are allergic to sirolimus or any of the
other ingredients in Rapamune. Symptoms of an allergic reaction include swelling
of your face, eyes, or mouth; trouble breathing or wheezing; throat tightness;
chest pain or tightness; feeling dizzy or faint; and rash or peeling of your
* Before taking Rapamune, tell your doctor if you have liver problems, skin
cancer or it runs in your family, high cholesterol or triglycerides, are
breastfeeding or plan to breastfeed, and are pregnant or plan to become
pregnant. Women of childbearing potential should use effective birth control
before therapy, during therapy, and for 12 weeks after Rapamune therapy has been
stopped. Rapamune may interact with other medicines. Make sure that your doctor
is aware of all prescription and over-the-counter drugs that you are taking,
including vitamins, herbs, and nutritional supplements. 
* Rapamune may cause swelling in your hands, feet, and in various tissues of
your body. Call your doctor if you have trouble breathing.
* Rapamune may cause your wounds to heal slowly or not heal well resulting in
redness, drainage, or opening of the wound.
* Rapamune may increase the levels of cholesterol and triglycerides (lipids or
fat) in your blood. Your doctor should do blood tests to check your lipids
during treatment with Rapamune. Your doctor may recommend treatment if your
lipid levels become too high. Your lipid levels may remain high even if you
follow your prescribed treatment plan.
* In patients taking Rapamune with cyclosporine, decreased kidney function has
been observed. Your doctor will regularly check your kidney function. 
* Rapamune may increase protein in your urine. Your doctor may monitor you for
abnormal protein in your urine from time to time. 
* Rapamune may increase your risk for viral infections. Certain viruses can live
in your body and cause active infections when your immune system is weak. One of
these viruses, BK virus, can affect how your kidney works and cause your
transplanted kidney to fail. A certain virus can cause a rare serious brain
infection called Progressive Multifocal Leukoencephalopathy causing death or
severe disability.
* Rapamune may cause potentially life-threatening lung or breathing problems.
Symptoms may include coughing, shortness of breath, or difficulty breathing.
* When Rapamune is taken with cyclosporine or tacrolimus, you may develop a
blood clotting problem resulting in unexplained bleeding or bruising.
* Common side effects associated with Rapamune include high blood pressure, pain
(including stomach and joint pain), diarrhea, headache, fever, urinary tract
infection, low red blood cell count (anemia), nausea, and low platelet count
(cells that help blood to clot). If you experience any side effects, contact
your doctor.

Indications and Usage

RAPAMUNE (sirolimus) is indicated for the prevention of organ rejection in
kidney transplant patients aged 13 years or older. Blood levels of sirolimus
should be checked in all patients taking Rapamune.

* In patients at low to moderate risk of acute rejection, it is recommended that
Rapamune be used initially in combination with cyclosporine and corticosteroids;
cyclosporine should be withdrawn approximately 3 months after transplantation.
Cyclosporine withdrawal has not been studied in patients who have had severe
acute rejection prior to cyclosporine withdrawal, those who require dialysis or
have a high serum creatinine, Black patients, patients receiving a repeat kidney
transplant, patients receiving other transplanted organs besides the kidney
transplant, or patients with antibodies that may be directed against the kidney
* In patients at high risk of acute rejection (defined as Black patients and/or
patients receiving a repeat kidney transplant who lost a previous kidney
transplant from rejection and/or patients with high levels of antibodies that
may be directed against the kidney transplant), it is recommended that Rapamune
be used in combination with cyclosporine and corticosteroids for the first year
following transplantation. The safety and efficacy of this combination in
high-risk patients have not been studied beyond one year; therefore, after the
first year, adjustments to the immunosuppressive regimen may be considered by
your doctor.

In pediatric patients, the safety and efficacy of Rapamune have not been
established in kidney transplant patients less than 13 years old, or in patients
less than 18 years old who are considered at high risk of acute rejection.

* The safety and efficacy of Rapamune without cyclosporine in newly transplanted
kidney patients have not been established.

* The safety and efficacy of changing from either cyclosporine or tacrolimus to
Rapamune in maintenance kidney transplant patients have not been established.

Please see full Prescribing Information for Rapamune, including Boxed Warning
and Medication Guide here.

Pfizer Inc.
Media Relations
Steve Danehy, 212-733-1538
Cell: 978-273-3946
Investor Relations
Suzanne Harnett, 212-733-8009 

Copyright Business Wire 2013